Literature DB >> 16098493

Effect of saccharide length on the immunogenicity of neoglycoconjugates from synthetic fragments of the O-SP of Vibrio cholerae O1, serotype Ogawa.

Rina Saksena1, Xingquan Ma, Terri K Wade, Pavol Kovác, William F Wade.   

Abstract

A synthetic hexasaccharide, identical to the terminal hexasaccharide of Ogawa LPS, coupled to bovine serum albumin induced protective antibodies in mice. To determine if there was a minimum saccharide length required for immunogenicity and efficacy, shorter (mono- to pentasaccharide) neoglycoconjugates (CHO-BSA) were tested in mice. The Ogawa CHO-BSA was inoculated at either a constant mass but differing moles, or equal moles but differing masses. Humoral responses were essentially the same when mice received 9 microg of the carbohydrate (0.007 mM with the pentasaccharide) in each of the neoglycoconjugates prepared from mono- through the pentasaccharide, or the same molar amount (0.007 mM), proportionally less by weight when going from the penta- to the monosaccharide. These data show that, within this dose range, the responses occurred virtually independently of the amount of immunogen. Humoral antibodies induced by these immunogens were generally not vibriocidal. Selected antisera induced by CHO-BSA immunogens were protective, but the ELISA titers of the sera were not predictive of the protective capacity. Purified, Ogawa LPS induced anti-Ogawa LPS IgM antibody titers similar to those induced by the Ogawa CHO-BSA conjugates. The anti-whole LPS sera were strongly vibriocidal, as were the previously reported sera induced by hexasaccharide conjugates. This suggests either that the shorter oligosaccharides lack a conformational epitope provided by the hexasaccharide or that the LPS has additional B cell epitopes or selects different B cells in the primary response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098493     DOI: 10.1016/j.carres.2005.07.017

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  7 in total

1.  Total synthesis of an antigenic heptasaccharide motif found in the cell-wall lipooligosaccharide of Mycobacterium gordonae strain 989.

Authors:  Chinmoy Mukherjee; Anup Kumar Misra
Journal:  Glycoconj J       Date:  2008-02-19       Impact factor: 2.916

2.  Immunochemical characterization of synthetic hexa-, octa- and decasaccharide conjugate vaccines for Vibrio cholerae O:1 serotype Ogawa with emphasis on antigenic density and chain length.

Authors:  Peter Ftacek; Victor Nelson; Shousun C Szu
Journal:  Glycoconj J       Date:  2013-08-17       Impact factor: 2.916

3.  Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice.

Authors:  Julianne E Rollenhagen; Anuj Kalsy; Rina Saksena; Alaullah Sheikh; Mohammad Murshid Alam; Firdausi Qadri; Stephen B Calderwood; Pavol Kovác; Edward T Ryan
Journal:  Vaccine       Date:  2009-06-27       Impact factor: 3.641

4.  Concise synthesis of the pentasaccharide O-antigen of Escherichia coli O83:K24:H31 present in the Colinfant vaccine.

Authors:  Pintu Kumar Mandal; Anup Kumar Misra
Journal:  Glycoconj J       Date:  2008-04-15       Impact factor: 2.916

5.  Multimeric bivalent immunogens from recombinant tetanus toxin HC fragment, synthetic hexasaccharides, and a glycopeptide adjuvant.

Authors:  Aileen F G Bongat; Rina Saksena; Roberto Adamo; Yukari Fujimoto; Zenyu Shiokawa; Dwight C Peterson; Koichi Fukase; Willie F Vann; Pavol Kovác
Journal:  Glycoconj J       Date:  2009-09-16       Impact factor: 2.916

6.  Investigation towards bivalent chemically defined glycoconjugate immunogens prepared from acid-detoxified lipopolysaccharide of Vibrio cholerae O1, serotype Inaba.

Authors:  Cyrille Grandjean; Alain Boutonnier; Bruno Dassy; Jean-Michel Fournier; Laurence A Mulard
Journal:  Glycoconj J       Date:  2008-07-23       Impact factor: 2.916

7.  Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice.

Authors:  A A Tarique; A Kalsy; M Arifuzzaman; S M Rollins; R C Charles; D T Leung; J B Harris; R C Larocque; A Sheikh; M S Bhuiyan; R Saksena; J D Clements; S B Calderwood; F Qadri; P Kovác; E T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-02-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.